Veterinary protocol for cellular regeneration

• US 20060140915A1
• Filed: 12/28/2004
• Published: 06/29/2006
• Est. Priority Date: 12/28/2004
• Status: Abandoned Application

• Current Assignee: Richard A. Schatz, William Hd De Burgh
• Original Assignee: Richard A. Schatz, William Hd De Burgh
• Inventors: Schatz, Richard A., de Burgh, William H. D.
• Application Number:
  US11/024,188
• Publication Number:
  US 20060140915A1
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 38/1866 Vascular endothelial growth factor [VEGF]
• CPC Class Codes: A61K 48/005 characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered

Abstract

A medicament and corresponding treatment protocol for in-vivo cellular regeneration within a mammal is described. Applications include the treatment of injuries to bone, cartilage, ligaments and tendons in humans and animals. Treatment includes the step of administering one or more therapeutically effective doses of medicament into an injured, living mammal. For the treatment, the medicament includes a plurality of stem cells and an angiogenic factor such as vascular endothelial growth factor (VEGF). In one implementation, non-embryonic stem cells are harvested from the mammal after injury for use in the medicament. Once harvested, the stem cells are typically concentrated (by removing non-stem cells from the harvested cell population) in a laboratory and then mixed with angiogenic factor to prepare the medicament. In an exemplary procedure, approximately ten therapeutically effective doses are injected into the body at or near the injured tissue during a healing period following the injury.

Claims

1. A method for in-vivo cellular regeneration in a mammal, said method comprising the step of administering a therapeutically effective dose of medicament into the living mammal, said medicament including a plurality of stem cells and an angiogenic factor.

2. A method as recited in claim 1 wherein said angiogenic factor is a vascular endothelial growth factor (VEGF).

3. A method as recited in claim 1 wherein said stem cells are harvested from the living mammal.

4. A method as recited in claim 3 wherein said stem cells are harvested from adipose tissue.

5. A method as recited in claim 1 wherein said stem cells are non-embryonic stem cells.

6. A method as recited in claim 1 wherein said medicament is administered to regenerate bone tissue.

7. A method as recited in claim 1 wherein said medicament is administered to regenerate cartilage tissue.

8. A method as recited in claim 1 wherein said medicament is administered to regenerate ligament tissue.

9. A method as recited in claim 1 wherein said medicament is administered to repair injured tissue.

10. A method as recited in claim 9 wherein said medicament is injected into the injured tissue.

11. A method as recited in claim 1 wherein said medicament is administered intramuscularly.

12. A method as recited in claim 1 wherein said medicament is administered intravenously.

13. A method as recited in claim 1 wherein said medicament is administered intra-arterially.

14. A method as recited in claim 1 wherein said mammal is a horse.

15. A method as recited in claim 1 wherein said plurality of stem cells is introduced into the living mammal separately from said angiogenic factor.

16. A method as recited in claim 1 wherein said angiogenic factor is introduced into the living mammal as a protein.

17. A method as recited in claim 1 wherein said angiogenic factor is introduced into the living mammal as a DNA plasmid.

18. A method as recited in claim 17 wherein said DNA plasmid is introduced using a vector selected from the group of vectors consisting of a viral vector, a liposome vector and an ultrasound vector.

19. A method as recited in claim 1 wherein said medicament is administered topically.

20. A method as recited in claim 19 wherein said medicament is applied directly to tissue using a bio-absorbable polymer mesh loaded with said stem cells and said angiogenic factor.

21. A method for in-vivo cellular regeneration in a mammal, said method comprising the steps of:

harvesting a population of cells from said living mammal, said population having stem cells and non-stem cells;

removing a portion of the non-stem cells from said cell population to produce a concentrated cell population; and

introducing said concentrated cell population and an angiogenic factor into said living mammal to regenerate tissue therein.

22. A method as recited in claim 21 further comprising the steps of:

mixing said concentrated cell population and said angiogenic factor to establish a mixture; and

apportioning the mixture into a plurality of therapeutically effective doses, each said dose being efficacious to regenerate a target type of tissue cell.

23. A method as recited in claim 22 wherein each said dose includes between approximately 200 mcg and approximately 100 mg vascular endothelial growth factor (VEGF) and between approximately 5 million and approximately 500 million stem cells.

24. A method as recited in claim 22 wherein said plurality of therapeutically effective doses is in a range of two to ten doses.

25. A system for in-vivo cellular regeneration in a mammal, said system comprising:

a means for surgically harvesting a population of cells from said living mammal;

a means for removing a portion of non-stem cells from said cell population to produce a concentrated cell population; and

a means for introducing said concentrated cell population and an angiogenic factor into said living mammal to regenerate tissue therein.

26. A system as recited in claim 25 wherein said introducing means comprises a syringe.

27. A medicament for in-vivo cellular regeneration in a living mammal, said medicament comprising:

a plurality of stem cells harvested from said living mammal; and

a vascular endothelial growth factor (VEGF).